At Synlogic, we are working to develop potential biotherapeutics based on synthetic biology to treat disease in new ways. We know patients are waiting for new treatment options and we are working tirelessly to make a difference.
Clinical trials are a critical way to study new drugs and advance research. They are a required step to bring any potential new therapy to those in need. Patient community participation in clinical trials can improve the clinical trial process in many ways. Patients help to advance understanding of disease and could affect how patients are treated for generations to come. Without patient involvement, new drugs cannot be approved.
We know that participating in a clinical trial is not always easy. We are grateful to the participants in our programs and in clinical trials around the world. They are true partners in science and innovation as we work together to create potential new treatment options.
Phenylketonuria (PKU) Clinical Trial Program
People living with PKU are not able to break down the amino acid phenylalanine (Phe) found in the natural protein in many foods, including all meat and dairy, as well as breads and cereals. The buildup of Phe can be neurotoxic, meaning dangerous for the brain. Synlogic has developed a potential therapy for PKU that has been designed to break down Phe. The potential therapy is a specially engineered probiotic that is taken orally (as a powder, mixed with a liquid like water). Synlogic has a clinical trial program, called Synpheny, to evaluate this potential therapy.
Following positive top-line Phase 2 results, SYNB1934 is expected to advance to the pivotal Phase 3 study initiation in the first half of 2023. To receive updates about our PKU program, submit your information to stay connected.
Homocystinuria (HCU) Clinical Trial Program
SYNB1353, a potential treatment for HCU, is a genetically engineered probiotic designed to consume methionine, a precursor to homocysteine, in the GI tract. The goal of treatment in HCU is to lower and control levels of total homocysteine (tHcy). SYNB1353 has achieved proof of mechanism in a Phase 1 study using a dietary model of homocystinuria in healthy volunteers.
To receive updates about our HCU program, please email: email@example.com
Enteric Hyperoxaluria (EH) Clinical Trial Program
Enteric hyperoxaluria (EH) is a well-recognized cause of recurrent kidney stones. It is a chronic, progressive disease caused by different gastrointestinal (GI) conditions, such as surgery or inflammatory bowel disease like Crohn’s disease. SYNB8802 is an investigative therapy that Synlogic designed to break down oxalate in the GI tract, which then lowers levels of oxalate in the urine, thereby lowering the risk of crystal formation.
SYNB8802 has demonstrated proof of concept through positive and clinically significant lowering of urinary oxalate in a Phase 1b study in patients with a history of gastric bypass surgery.
To receive updates about our EH program, please email: firstname.lastname@example.org